ARS Pharmaceuticals's total assets for Q3 2025 were $372.80M, an increase of 18.93% from the previous quarter. SPRY total liabilities were $225.15M for the fiscal quarter, a 85.84% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.